Tag : HIV1

Latest News

The Safety and Immunogenicity of GTU (R) MultiHIV DNA Vaccine Delivered by Transcutaneous and Intramuscular Injection With or Without Electroporation in HIV-1 Positive Subjects on Suppressive ART

Newsemia
Haidari, G; Day, S; Wood, M; Ridgers, H; Cope, A; Fleck, S; Yan, C; … Shattock, RJ; + view all Haidari, G; Day, S; Wood,...
Pharma / Biotech

Raltegravir (RAL) in neonates: Dosing, pharmacokinetics (PK), and safety in HIV-1 exposed neonates at risk of infection (IMPAACT P1110).

Newsemia
Raltegravir (RAL) in neonates: Dosing, pharmacokinetics (PK), and safety in HIV-1 exposed neonates at risk of infection (IMPAACT P1110). J Acquir Immune Defic Syndr. 2020...
AI/ML

HIVCoR: A sequence-based tool for predicting HIV-1 CRF01_AE coreceptor usage.

Newsemia
Related Articles HIVCoR: A sequence-based tool for predicting HIV-1 CRF01_AE coreceptor usage. Comput Biol Chem. 2019 Jun;80:419-432 Authors: Hongjaisee S, Nantasenamat C, Carraway TS, Shoombuatong...
AI/ML

Drivers of HIV-1 transmission: The Portuguese case.

Newsemia
Related Articles Drivers of HIV-1 transmission: The Portuguese case. PLoS One. 2019;14(9):e0218226 Authors: Pineda-Peña AC, Pingarilho M, Li G, Vrancken B, Libin P, Gomes P,...
Pharma / Biotech

Safety, Tolerability, and Pharmacokinetics of the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 in HIV-Exposed Newborn Infants.

Newsemia
Related Articles Safety, Tolerability, and Pharmacokinetics of the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 in HIV-Exposed Newborn Infants. J Infect Dis. 2019 Nov 04;: Authors:...
Latest News

ViiV Healthcare announces phase III study meets primary endpoint, demonstrating the ability to control HIV-1 with a 2-drug regimen of dolutegravir plus lamivudine in virally suppressed patients switching from a TAF-containing, 3-drug regimen

Newsemia
LONDON–(BUSINESS WIRE)–ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced positive Week 48 results...
Pharma / Biotech

Effect of Anti-CD4 Antibody UB-421 on HIV-1 Rebound after Treatment Interruption.

Newsemia
Related Articles Effect of Anti-CD4 Antibody UB-421 on HIV-1 Rebound after Treatment Interruption. N Engl J Med. 2019 Apr 18;380(16):1535-1545 Authors: Wang CY, Wong WW,...
Pharma / Biotech

A potential long-acting bictegravir loaded nano-drug delivery system for HIV-1 infection: A proof-of-concept study.

Newsemia
Related Articles A potential long-acting bictegravir loaded nano-drug delivery system for HIV-1 infection: A proof-of-concept study. Antiviral Res. 2019 Apr 13;: Authors: Mandal S, Prathipati...
Biology

CD4 occupancy triggers sequential pre-fusion conformational states of the HIV-1 envelope trimer with relevance for broadly neutralizing antibody activity

Newsemia
by Branislav Ivan, Zhaozhi Sun, Harini Subbaraman, Nikolas Friedrich, Alexandra Trkola During the entry process, the human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein (Env)...
AI/ML

Optimized Virtual Screening Workflow: Towards Target-Based Polynomial Scoring Functions for HIV-1 Protease.

Newsemia
Related Articles Optimized Virtual Screening Workflow: Towards Target-Based Polynomial Scoring Functions for HIV-1 Protease. Comb Chem High Throughput Screen. 2017;20(9):820-827 Authors: Pintro VO, de Azevedo...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy